Uterine leiomyomas (also known as uterine fibroids) are the most common benign tumors of female reproductive tract and are the single most common indication for hysterectomies. Despite their high prevalence, the exact pathogenesis of these benign tumors is still unknown. One possible mechanism for leiomyoma formation is dysregulation of mesenchymal stem cell activity. Mesenchymal stem cells have been identified in both human and murine uteri and cancer stem cells have been identified in female reproductive malignancies. We compared stem/progenitor cell characteristics in both normal myometrium and the corresponding leiomyoma of patient’s undergoing hysterectomies. We found that leiomyoma cells form fewer mesenchymal stem cell colonies and exhibit less Hoechst dye-excluding side population (SP) activity, which is a function associated with progenitor cells in other tissues, than cells isolated from normal myometrium. Whereas in normal myometrium, we observed heterogeneous expression of CD90, a cell surface marker associated the with differentiation potential of uterine fibroblasts, in leiomyomas, we observed homogenous expression of CD90, suggesting leiomyoma cells are more terminally differentiated. Furthermore, we found that while leiomyoma cells could only produce CD90 expressing cells, both CD90+ and CD90— myometrial cells could reestablish their original heterogeneous CD90 profile when expanded in vitro. These results suggest that normal myometrium contains cells with stem/progenitor cell activities that are absent in leiomyomas.
Stewart EAUterine fibroids. Lancet. 2001;357(9252):293-298.
2.
Jordan CT, Guzman ML, Noble M.Cancer stem cells. N Engl J Med. 2006;355(12):1253-1261.
3.
Schofield R.The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4(1-2):7-25.
4.
Al-Hajj M., Wicha MS, Benito-Hernandez A., Morrison SJ, Clarke MFProspective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7): 3983-3988.
5.
Szotek PP, Pieretti-Vanmarcke R., Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006;103(30): 11154-11159.
6.
Zhang S., Balch C., Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311-4320.
7.
Haeryfar SM, Hoskin DWThy-1: more than a mouse pan-T cell marker. J Immunol. 2004;173(6):3581-3588.
8.
Rege TA, Hagood JSThy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 2006; 20(8):1045-1054.
9.
Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B.Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A. 1992;89(7): 2804-2808.
10.
Dominici M. , Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
11.
Koumas L., King AE, Critchley HO, Kelly RW, Phipps RPFibroblast heterogeneity: existence of functionally distinct Thy 1(+) and Thy 1(-) human female reproductive tract fibroblasts. Am J Pathol. 2001;159(3):925-935.
12.
Petersen BE , Goff JP, Greenberger JS, Michalopoulos GKHepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology. 1998;27(2):433-445.
13.
Schwab KE, Hutchinson P., Gargett CEIdentification of surface markers for prospective isolation of human endometrial stromal colony-forming cells. Hum Reprod. 2008;23(4):934-943.
14.
Koumas L., Smith TJ, Feldon S., Blumberg N., Phipps RPThy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003; 163(4):1291-1300.
15.
Preffer FI, Dombkowski D., Sykes M., Scadden D., Yang YGLineage-negative side-population (SP) cells with restricted hematopoietic capacity circulate in normal human adult blood: immunophenotypic and functional characterization. Stem Cells. 2002;20(5):417-427.
16.
Szotek PP, Chang HL, Zhang L., et al. Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells. 2007 ;25(5):1317-1325.
17.
Ono M., Maruyama T., Masuda H., et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A. 2007;104(47):18700-18705.
18.
Dixon D., Flake GP, Moore AB, et al. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002;441(1):53-62.
19.
Kayisli UA, Berkkanoglu M., Kizilay G., Senturk L., Arici A.Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle. Reprod Sci. 2007;14(7):678-686.
20.
Bodner K., Bodner-Adler B., Kimberger O., Czerwenka K., Mayerhofer K.Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig. 2004;11(3):187-191.
21.
Huang SC, Tang MJ, Hsu KF, Cheng YM, Chou CYFas and its ligand, caspases, and bcl-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma. J Clin Endocrinol Metab. 2002;87(10):4580-4586.
22.
Wu X., Blanck A., Olovsson M., Henriksen R., Lindblom B.Expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. J Steroid Biochem Mol Biol. 2002; 80(1):77-83.
23.
Carney SA, Tahara H., Swartz CD, et al. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics . Lab Invest. 2002;82(6):719-728.
24.
Loy CJ, Evelyn S., Lim FK, Liu MH, Yong ELGrowth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod. 2005;11(8):561-566.
25.
Morrison SJ, Spradling ACStem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008;132(4):598-611.
26.
Goodell MA, Brose K., Paradis G., Conner AS, Mulligan RCIsolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183(4):1797-1806.
27.
Haraguchi N., Utsunomiya T., Inoue H., et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006;24(3):506-513.
28.
Wulf GG, Wang RY, Kuehnle I., et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98(4):1166-1173.
29.
Kato K., Yoshimoto M., Adachi S., et al. Characterization of side-population cells in human normal endometrium . Hum Reprod. 2007;22(5):1214-1223.
30.
Tsuji S., Yoshimoto M., Takahashi K., Noda Y., Nakahata T., Heike T.Side population cells contribute to the genesis of human endometrium. Fertil Steril. 2008;90(4 suppl):1528-1537.
31.
Koumas L., Phipps RPDifferential COX localization and PG release in Thy-1(+) and Thy-1(-) human female reproductive tract fibroblasts. Am J Physiol Cell Physiol . 2002;283(2): C599-C608.
32.
Arici A., Sozen I.Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73(5):1006-1011.
33.
Luo X., Ding L., Xu J., Chegini N.Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology . 2005;146(3): 1097-1118.
34.
Sozen I., Arici A.Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril . 2002;78(1):1-12.
